期刊
PHARMACOLOGY & THERAPEUTICS
卷 190, 期 -, 页码 81-90出版社
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.pharmthera.2018.04.005
关键词
Non-alcoholic fatty liver disease; Bile acids; Lipid metabolism; Inflammation; BA-activated receptor
资金
- National Natural Science Foundation of China [81320108029, 81573514, 81773827, 81773995]
- National Major Scientific and Technological Special Project for Significant New Drugs project [2015ZX09501004-002-004]
- Specific Fund for Public Interest Research of Traditional Chinese Medicine, Ministry of finance [201507004-002]
Non-alcoholic fatty liver disease (NAFLD) is characterized by excessive fat deposition in the liver in the absence of significant alcohol consumption. Dysregulated bile acid (BA) metabolism is an important indicator in the pathology of NAFLD, which could progress into more severe forms of liver injury. Lipid metabolism, immune environment and intestinal bacteria are all affected by dysregulated BA metabolism directly, but the mechanisms remain unclear. Several drug candidates that target BA metabolism, either used alone or in combination with other agents, are currently under development for treatment of NAFLD. Here, we summarize the relationship of dysregulated BA metabolism and NAFLD, discuss the effects and mechanisms of dysregulated BAs-induced lipid metabolism disorder. Challenges in developing novel treatments are also discussed. (C) 2018 Elsevier Inc All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据